Clinical Trials Logo

Clinical Trial Details — Status: No longer available

Administrative data

NCT number NCT03460782
Other study ID # PST-9-IP
Secondary ID
Status No longer available
Phase
First received
Last updated

Study information

Verified date November 2019
Source Center Trials & Treatment
Contact n/a
Is FDA regulated No
Health authority
Study type Expanded Access

Clinical Trial Summary

IPILIMUMAB Extended Access Program for patients who received chemotherapy and / or radiation therapy before the protocol, before or after the operation.


Description:

It is not yet known which protocols are a better treatment for glioblastoma or glioma.

The ipilimumab extended-access program for patients who received previous chemotherapy and / or radiation therapy by protocol, before ((for non-operable cases) or after the operation.

Monoclonal antibodies of CTLA-4, such as ipilimumab, may block tumor growth in different ways by targeting certain cells and activating the patient's immune system to fight the disease.


Recruitment information / eligibility

Status No longer available
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Glioblastoma.

- Glioma Brain.

- Male or female subjects aged =18 years.

- Histopathological evidence of glioblastoma or glioma.

- Patients still alive must provide informed consent if required by local regulations

- Maximal tumor diameter (including residual tumor and resection cavity if subjects had tumor resection rather than only stereotactic biopsy) up to 7cm or less.

- Karnofsky performance status (Appendix 2) of =60.

- Availability of a paraffin-embedded or frozen tumor-tissue block with a minimum of 0.5 cm2 and 5 unstained slides from the glioblastoma or glioma tissue specimen.

- Not earlier than 35 days after surgery.

- An interval of at least 2 week for stereotactic biopsy from the start of study treatment.

- A contrast-enhanced MRI must be obtained within 7 days of the first dose of study treatment.

- Adequate hematologic, hepatic, and renal function defined by test

- Women must have a negative serum or urine pregnancy test before 24 hours of initiation of study drug.

- Any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL to be defined as post-menopausal.

Women receiving ipilimumab will be instructed to adhere to contraception for a period of 35 weeks after the last dose of program.

- Men receiving ipilimumab and who are sexually active will be instructed to adhere to contraception for a period of 39 weeks after the last dose of program.

- Contraception is not required for men with documented vasectomy.

- Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.

- Women must not be breastfeeding.

- Willing to and capable of providing written informed consent prior to any program related procedures.

- Ability and willingness to comply scheduled visits, treatment plans, laboratory tests, and other program-related procedures.

Exclusion Criteria:

- Prior systemic treatment anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways.

- Planned participation in another study intended for therapy of glioma or glioblastoma.

- Primary brainstem or spinal cord tumor.

- Diffuse leptomeningeal gliomatosis.

- ?onfirmed mutation of the IDH1/2 genes.

- Stem or dendritic cell therapy 60 days before the program or 45 days after the last infusion of ipilimumab.

- Systemic treatment with either immunosuppressive doses of corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 21 days of study drug administration.

- Patients on a standard high-dose steroid taper after craniotomy or stereotactic biopsy may have received a higher dose of corticosteroids within 21 days of registration, however must be at a dose < 5 mg daily prednisone or bioequivalent per day within 7 days prior to initiation of study drug.

- Patients requiring adrenal replacement with corticosteroids are eligible if the steroids are at doses = 10 mg prednisone or bioequivalent per day in the absence of active autoimmune disease.

- Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication) are allowed.

- Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent.

- Prior organ transplantation, including allogeneic stem cell transplantation.

- Known history of, or any evidence of active, non-infectious pneumonitis within the last 5 years.

- Known severe (NCI-CTCAE v4.03 Grade 3 or 4) infusion-related allergy or acute hypersensitivity reaction attributed to any monoclonal antibody, any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma).

- Unable tolerate an MRI, or have a contraindication to MRI.

- Active infection requiring systemic therapy.

- Positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome.

- Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus (HCV antibody) indicating acute or chronic infection.

- Vaccination within 5 weeks of the first dose of study drug and while on trials is prohibited except for administration of inactivated vaccines.

ATTENTION: Seasonal influenza vaccines for injection are live attenuated vaccines, and are not allowed.

- Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (= NY Heart Association - CC II), or serious cardiac arrhythmia requiring medication.

- All other unstable, severe, or chronic medical or psychiatric conditions including colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis, recent (within the past year) or active suicidal idea in behavior, or laboratory abnormalities that may increase the risk associated with program or judgment of the investigator, would make the patient participation impossible.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Ipilimumab
Each patient receives Ipilimumab in regimen and dose according to the official manufacturer's instructions (IV 1 mg / kg every 6 weeks for maximum of 4 doses). Participation of the patient in the program must necessarily be agreed with the current treatment and contain a written agreement with the attending physician. This program is not covered by health insurance. For patients in the postoperative period to provide a mandatory conclusion of histology and molecular-genetic for the identified mutations and the type of tumor.

Locations

Country Name City State
Albania University "Mother Theresa" Hospital Center; Oncology Department Tirana
Bosnia and Herzegovina University Clinical Center of the Republic of Srpska Banja Luka
Bulgaria Complex Oncology Center Plovdiv
Croatia Clinical Hospital Osijek; Dept For Oncology & Radiotherapy Osijek
Romania Institut of Oncology Al. Trestioreanu Bucharest; Oncology Bucharest,
Russian Federation Regional Oncology Hospital Irkutsk
Russian Federation Rostov Cancer Research Institute Rostov-on-Don
Russian Federation Primorsky Regional Oncology Center Vladivostok
Serbia Clinical Hospital Center Bezanijska kosa; Clinic for Oncology Belgrade
Switzerland Inselspital Bern; Medizinische Onkologie Bern
Switzerland Stadtspital Triemli; Frauenklinik Zürich

Sponsors (2)

Lead Sponsor Collaborator
Center Trials & Treatment BioGene Pharmaceutical Inc.

Countries where clinical trial is conducted

Albania,  Bosnia and Herzegovina,  Bulgaria,  Croatia,  Romania,  Russian Federation,  Serbia,  Switzerland, 

See also
  Status Clinical Trial Phase
Recruiting NCT05664243 - A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT02768389 - Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma Early Phase 1
Recruiting NCT05635734 - Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT03679754 - Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 Phase 1
Completed NCT01250470 - Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma Phase 1
Terminated NCT03927222 - Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma Phase 2
Recruiting NCT03897491 - PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma Phase 2
Active, not recruiting NCT03587038 - OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma Phase 1
Completed NCT01922076 - Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Phase 1
Recruiting NCT04391062 - Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma Phase 2
Active, not recruiting NCT03661723 - Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma Phase 2
Active, not recruiting NCT02655601 - Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 Phase 2
Completed NCT02206230 - Trial of Hypofractionated Radiation Therapy for Glioblastoma Phase 2
Completed NCT03493932 - Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade Phase 1
Terminated NCT02709889 - Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Phase 2
Completed NCT03018288 - Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) Phase 2
Not yet recruiting NCT04552977 - A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma Phase 2
Withdrawn NCT03980249 - Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells Early Phase 1
Terminated NCT02905643 - Discerning Pseudoprogression vs True Tumor Growth in GBMs